Jenna Rimel
About Jenna Rimel
Jenna Rimel - Scientist
Jenna Rimel is a scientist with a focus on target discovery and validation for transcriptional addiction mechanisms in cancer. Her expertise lies in the specialized field of transcriptional biology, particularly RNA Pol II mediated transcription. Jenna's research approach is grounded in understanding the complex mechanisms of transcription and its implications in disease, especially cancer. This technical knowledge positions her as a valuable contributor to advancements in cancer research and therapeutics.
Jenna Rimel's Education and Expertise
Jenna Rimel received her PhD from the University of Colorado. Her doctoral research concentrated on the mechanisms of RNA Pol II mediated transcription. This advanced training provided Jenna with a robust foundation in molecular biology and transcriptional mechanisms, particularly RNA polymerase II, a vital enzyme in the transcription process. This background has equipped her with the skills necessary to explore and understand intricate cellular processes and their implications in cancer biology.
Jenna Rimel's Collaboration with Syros Pharmaceuticals
Jenna Rimel collaborated with Syros Pharmaceuticals on the development of a novel CDK7 inhibitor. CDK7 inhibitors are an exciting area of research in cancer therapy as they target transcriptional regulation at a key point. This collaboration highlights Jenna's ability to engage in cutting-edge pharmaceutical research and contribute to the development of innovative therapeutic solutions. Her work with Syros Pharmaceuticals underscores her commitment to translational science and improving outcomes for cancer patients.
Focus on Transcriptional Addiction Mechanisms in Cancer
Jenna Rimel's scientific investigations primarily focus on the target discovery and validation of transcriptional addiction mechanisms in cancer. Transcriptional addiction is a concept where cancer cells become highly dependent on specific transcriptional programs for survival. Jenna's research aims to identify and validate these critical transcriptional targets, potentially leading to novel therapeutic strategies. Her work addresses key challenges in cancer biology and aims to uncover vulnerabilities in cancer cells that could be exploited for treatment.